At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 56 enrolled
Drug / intervention
Placebos +1 moredrug
Likely dose
Leronlimab (700mg)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab in Patients Experiencing Prolonged Coronavirus Disease 2019 (COVID-19) Symptoms [Long-Haulers]
In Brief
A Phase 2 clinical trial evaluating Placebos and Leronlimab (700mg) for Coronavirus Disease 2019. Completed, enrolled 56 participants across 2 sites.
Detailed Summary
The purpose of this study is to assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injections in subjects experiencing prolonged symptoms (\> 12 weeks) of COVID-19.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronavirus Disease 2019
CountriesUnited States
CollaboratorsAmarex Clinical Research
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartMar 2021
Primary CompletionJun 2021
Study CompletionJul 2021
TodayJul 2026
First PostedDec 22, 2020
Enrollment StartMar 1, 2021
Primary CompletionJun 5, 2021
Study CompletionJul 8, 2021
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 5.5 years ago
Interventions
Placebosdrug
Placebos
Leronlimab (700mg)drug
Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)